Regeneron’s Antibody Cocktail Shows Promise In Covid Patient Trials
A mixed shot of casirivimab and imdevimab, covid antibody products developed by Regeneron and Roche, is shown to reduce hospitalizations and deaths by 70% in a new study.
Bloomberg:
Regeneron Antibody Cocktail Cuts Hospitalization Rate By 70%
Regeneron Pharmaceuticals Inc. said it would apply for U.S. authorization for a lower dose of its Covid-19 antibody cocktail, after data from a final-stage trial showed early use of the drug reduced hospitalizations and deaths by 70%. The Food and Drug Administration in November cleared Regeneron’s therapy for emergency use. The treatment is part of a class of therapies that were widely hailed for their effectiveness, though the drugs have been slow to be widely adopted because they are difficult to administer. (Langreth, 3/23)
CNBC:
Roche Antibody Cocktail Shown Effective In Covid Patients
New late-stage trial data show Regeneron and Roche’s antibody cocktail against Covid-19 cut hospitalization or death by 70% versus a placebo in non-hospitalized patients, the Swiss drugmaker said on Tuesday. The shot, consisting of casirivimab and imdevimab antibodies developed by Regeneron with financial help from the U.S. government, also met all key secondary endpoints in the phase III trial with 4,567 participants, including reducing symptom duration to 10 days from 14, Roche said. (3/23)
The Wall Street Journal:
Regeneron Covid-19 Antibody Drug Reduced Risk Of Hospitalization, Death By 70% In Late-Stage Trial
Among subjects in a late-stage trial receiving a lower dose of the antibody drug, 1% were hospitalized or died, compared with 3.2% of patients receiving placebos, Regeneron said Tuesday. Study subjects getting a higher dose had a similar risk reduction, the company said. (Walker, 3/23)
